Explore Our Library of Biomanufacturing Resources & Technical Data

Blog

3 Takeaways from the World Vaccine Congress 2018

Albumin in Drug Delivery: Cancer’s Unexpected Achilles’ Heel

ASGCT 2019: Remarkable Milestones and Achievements in Cell and Gene Therapy

BIO 2018: The Emergence of Gene & Cell Therapy

BIO Europe 2018: From Lab Innovations to Commercial Realities

BioInnovation on Parade: Philly Stands Proud for BIO 2019!

Controlling Impurities in Cell Culture Media

Cryopreservation Just Got Better with Optibumin® 25

ECI Conference 2019: The Latest Innovations and Trends in Cell & Gene Therapy

Evolving Challenges in Closed-System Biomanufacturing

Explore the Latest Developments in T-reg Research and Clinical Application

Exploring the Latest Research and Opportunities in T-reg Therapy

Happy Holidays from the InVitria Team!

High-Performance Production of Viral Vectors for Cell and Gene Therapy Using OptiPEAK HEK293t Complete Media

How Regulatory Bodies Are Driving the Shift to Animal-Origin-Free Solutions in Cell Therapy and Vaccine Development

Innovative Solutions in Closed-System Biomanufacturing: Exploring the Tools and Technologies Driving Sterility and Efficiency

InVitria at the American Association of Immunologists 2018 Conference

InVitria Expands Operations to Anschutz Medical Campus in the Denver Metro Area

InVitria’s Top Insights from ISCT 2018 – Montreal

Join InVitria at ECI 2019

Join InVitria at Phacilitate 2019

Optibumin vs Traditional Albumin: Comparing Performance in Cell Wash Applications

Phacilitate 2019 and World Stem Cell Summit

Recombinant Albumin for Stabilization of Live-Attenuated Viral Vaccines

Recombinant Virus Platforms are Out in Front in the Race to Develop Vaccines Against SARS-CoV-2 and COVID-19 Disease

SARS-CoV2 and Influenza – Double Threat

Scaling Innovation: How DiscGenics and InVitria are Leading the Future of Cell Therapy

Solving the Vaccine Supply Challenge

Universal Vaccine Against Seasonal Influenza Steps Closer to Reality with the Results of FluGen Phase 2 Clinical Trial

Why Border Disruptions Threaten Blood-Derived Raw Materials—and What Biomanufacturers Can Do About It

Why Do Some Biologics Cross the Finish Line—While Others Crash and Burn?